PICT ANTICOAGULANT MONITORING 1. PEFAKIT PICT. Clotting Assay. PEFAKIT PiCT. PEFAKIT PICT Calibrators UFH. PEFAKIT PICT Controls UFH
|
|
- Eleanor Parrish
- 6 years ago
- Views:
Transcription
1 PEFAKIT PiCT PEFAKIT PICT Calibrators UFH PEFAKIT PICT Controls UFH PEFAKIT PICT Calibrators LMWH Clotting Assay PICT 1. PEFAKIT PICT Package size kit 80 3 vials of PiCT Activator (2mL) 3 vials of PiCT Start Reagent (2 ml) Plasma based functional assay for the determination of Factor Xa and factor IIa inhibitors. PiCT relies on the activation of plasma directly at the level of the pro-thrombinase complex, resulting in a fine-tuned analytical output directly linked to antithrombotic drug content. RVV-V (a specific FV activator from aboia russelli) activates FV. In the presence of added phospholipids (mimicking platelet membranes or other negatively charged surfaces), a defined amount of FXa and calcium is added and the prothrombinase is rapidly formed. ue to the FV preactivation by means of RVV-V prothrombinase formation becomes solely dependent on the activity of FXa and FIIa in the sample. 5 PEFAKIT PICT Controls LMWH PiCT test principle Prothrombinase complex Phospholipids RVV-V Traditional coagulation tests such as aptt, PT, ECT, TT or anti-xa assays are of limited use for the monitoring of antithrombotic drugs since different assays are required for monitoring of different anticoagulants. Intrinsic pathway Ca ++ FXa / FVa FV Extrinsic pathway The most commonly used test, aptt, broadly used to monitor heparin, lacks consistency, results varying with reagent, instrument and drug. Chromogenic assays represent the gold standard in most cases, but require special instrumentation. A universal test adaptable to standard instruments would simplify monitoring antithrombotic therapy and minimize investment to the hemostasis lab by eliminating the need for adopting new tests as new antithrombotic drugs enter the market. Inhibition (LMWH) Prothrombin Fibrinogen Thrombin Fibrin Inhibition (UFH/hirudin) Clotting time 54
2 2. PEFAKIT PICT CALIBRATORS UFH 4. PEFAKIT PICT CALIBRATORS LMWH x 2 x 1.0 ml 3 vials of UFH Calibrator 1 (1 ml) 3 vials of UFH Calibrator 2 (1 ml) M x 2 x 1.0 ml 3 vials of LMWH Calibrator 1 (1 ml) 3 vials of LMWH Calibrator 2 (1 ml) M Calibrator plasmas for quantification of unfractionated heparins (UFH) with Pefakit PiCT. This kit contains vials of plasma with no UFH anticoagulant activity (CAL1, 0 IU/ml) and vials of plasma with high UFH anticoagulant activity (CAL2) calibrated against WHO UFH standard. Calibrator plasmas for the quantification of low molecular weight heparins (LMWH) with Pefakit PiCT This kit contains vials of plasma with no LMWH anticoagulant activity (CAL1, 0 IU/ml) and vials of plasma with high LMWH anticoagulant activity (CAL2) calibrated against WHO LMWH standard. 3. PEFAKIT PICT CONTROLS UFH 5. PEFAKIT PICT CONTROLS LMWH x 2 x 1.0 ml 3 vials of UFH Control 1 (1 ml) 3 vials of UFH Control 2 (1 ml) M x 2 x 1.0 ml 3 vials of LMWH Control 1 (1mL) 3 vials of LMWH Control 2 (1 ml) M Control plasmas for quantification of unfractionated heparins (UFH) with Pefakit PiCT Pefakit PiCT Controls UFH contains vials of plasma with low and high UFH anticoagulant activity (C1, C2). Unfractionated heparin (UFH) Control plasmas for the quantification of low molecular weight heparins (LMWH) with Pefakit PiCT Pefakit PiCT Controls LMWH contains vials of plasma with low and high LMWH anticoagulant activity (C1, C2). Low molecular weight heparin (LMWH) Clotting time on BCS (s) r 2 = ,0 0,5 1,0 1,5 2,0 UFH (UI/mL) Clotting time on BCS (s) r 2 = ,0 0,2 0,4 0,6 0,8 1,0 1,2 1,4 1,6 LMWH in UI / ml 55
3 Clotting Assay IRECT THROMBIN INHIBITORS 1.TECHNOCLOT TI Package size kit 2 x 20 tests 2 vials of Reagent 1 (R1): Normal Plasma, lyophilized (2 ml) 2 vials of Reagent 2 (R2): bovine thrombine (2 ml) TECHNOCLOT TI is used for the determination of anticoagulant activity of the direct thrombin inhibitor (TI) dabigatran in human citrated plasma. 1 2 TECHNOCLOT TI TECHNOVIEW abigatran cal set abigatran is the active component of the oral anticoagulant pro-drug, abigatran Etexilate which has been approved for various indications under the tradename Pradaxa.For measuring dabigatran in plasma, in a first step the diluted patient sample is mixed with normal human plasma reagent R1. Clotting is then initiated by adding the thrombin reagent R2. The clotting time measured is directly related to the concentration of the assayed dabigatran in the sample plasma. 3 TECHNOVIEW abigatran low control 4 TECHNOVIEW abigatran high control 5 TECHNOVIEW Argatroban Cal set 6 TECHNOVIEW Argatroban Low Control 7 TECHNOVIEW Argatroban High Control Test principle NEW abigatran time (s) r 2 = ng/ml Very good reproducibility abigatran ng/ml Argatroban time (s) r 2 = µg/ml Argatroban μg/ml intra-assay inter-assay intra-assay inter-assay Mean CV % TECHNOCLOT TI is used for the determination of anticoagulant activity of the direct thrombin inhibitor (TI) dabigatran in human citrated plasma. abigatran is the active component of the oral anticoagulant pro-drug, abigatran Etexilate which has been approved for various indications under the tradename Pradaxa.For measuring dabigatran in plasma, in a first step the diluted patient sample is mixed with normal human plasma reagent R1. Clotting is then initiated by adding the thrombin reagent R2. The clotting time measured is directly related to the concentration of the assayed dabigatran in the sample plasma. ng/ml iabagran abigatran: No interference with heparin 0,18 0 U/mL 0.8 U/mL 0,12 1 U/mL 0, U/mL 0,00 abigatran Control Low + UFH µg/ml Argatroban Argatroban: No interference with heparin U/mL 0.8 U/mL U/mL U/mL 0.00 Argatroban Control Low + LMWH 56
4 2. TECHNOVIEW ABIGATRAN CAL SET x 1.0 ml 4 vials of plasma (1 ml) Set of 4 calibrators with different concentrations of abigatran. The TECHNOVIEW ABIGATRAN Calibrator is prepared from citrated plasmas supplemented with different concentrations of abigatran using the TECHNOCLOT TI. 3. TECHNOVIEW ABIGATRAN LOW CONTROL x 1.0 ml 5 vials of plasma (1 ml) Control plasma with low concentration of abigatran ( 150 ng/ml). The TECHNOVIEW ABIGATRAN Low Control Plasma is prepared from citrated plasmas supplemented with a low concentrations of abigatran around 150 ng/ml. 4. TECHNOVIEW ABIGATRAN HIGH CONTROL x 1.0 ml 5 vials of plasma (1 ml) Control plasma with high concentration of abigatran ( 300 ng/ml). The TECHNOVIEW ABIGATRAN High Control Plasma is prepared from citrated plasmas supplemented with a high concentrations of abigatran around 300 ng/ml. The TECHNOVIEW abigatran Calibrator and Control Plasma Sets listed below are plasmas for calibration and quality control of the corresponding anticoagulant measurement, titrated and optimised using the TECHNOCLOT TI. 5. TECHNOVIEW ARGATROBAN CAL SET x 1.0 ml 5 vials of plasma (1 ml) Set of 4 calibrators with different concentrations of Argatroban (0 to 2 µg/ml). The TECHNOVIEW ARGATROBAN Calibrator is prepared from citrated plasmas supplemented with different concentrations of Argatroban using the TECHNOCLOT TI. 6. TECHNOVIEW ARGATROBAN LOW CONTROL x 1.0 ml 5 vials of plasma (1 ml) Control plasma with low concentration of Argatroban ( 0.7 µg/ml) The TECHNOVIEW ARGATROBAN Low Control Plasma is prepared from citrated plasmas supplemented with a low concentrations of Argatroban around 0.7 µg/ml. 7. TECHNOVIEW ARGATROBAN HIGH CONTROL x 1.0 ml 5 vials of plasma (1 ml) Control plasma with high concentration of Argatroban ( 1.2 µg/ml). The TECHNOVIEW ARGATROBAN High Control Plasma is prepared from citrated plasmas supplemented with a high concentrations of Argatroban around 1.2 µg/ml. The TECHNOVIEW Argatroban Calibrator and Control Plasma Sets listed below are plasmas for calibration and quality control of the corresponding anticoagulant measurement, titrated and optimised using the TECHNOCLOT TI. 57
5 1. TECHNOCHROM ANTI-Xa Chromogenic Assay ANTI-Xa Package size kit 80 1 vial of Reagent 1 (4 ml) 1 vial of Reagent 2 (4 ml) 1 vial of Reagent 3 (20 ml) M ANTI-Xa 1 TECHNOCHROM anti-xa UFH 2 Technoview UFH cal set 3 Technoview UFH cont low 4 Technoview UFH cont high LMW 5 Technoview LMW cal set A system of reagents for the chromogenic determination of direct and indirect Xa inhibitors in human citrated plasma. TECHNOCHROM anti-xa assay is based on the inhibition of activated factor X (FXa) by Antithrombin (AT) in the presence of heparin as measured by a chromogenic FXa substrate. The amount of pna, released by enzymatic hydrolysis, is measured at 405 nm. There is an inverse relationship between the amount of heparin present in the sample and colour development. Information Anticoagulant Linearity etection limit Fondaparinux (Arixtra ) μg/mL 0.07μg/mL LMWH IU/mL 0.05 IU/mL UFH IU/mL 0.06 IU/mL anaparoid (Orgaran ) IU/mL 0.08 U/mL Rivaroxaban (Xarelto ) ng/ml 10 ng/ml Technoview LMW cont low Technoview LMW cont medium Technoview LMW cont high 58
6 2. TECHNOVIEW UFH CAL SET 5. TECHNOVIEW LMW CAL SET x 1.0 ml Set of 5 plasmas for calibration of unfractionated Heparin (UFH) Calibrators are prepared from citrated plasmas supplemented with different concentrations of unfractionated Heparin x 1.0 ml Set of 5 plasmas for calibration of Low Molecular Weight (LMW) Heparin measurements titrated and optimised using anti-xa assays. Calibrator plasmas are prepared from citrated plasmas supplemented with different concentrations of LMW Heparin. 6. TECHNOVIEW LMW CONT LOW 3. TECHNOVIEW UFH CONT LOW x 1.0 ml Set of low control plasmas for quality control of unfractionated Heparin (UFH) Control plasmas are prepared from citrated plasmas supplemented with 0.2 IU/mL of unfractionated Heparin x 1.0 ml Set of low control plasmas for the quality control of Low Molecular Weight (LMW) Heparin Control Low plasmas are prepared from citrated plasmas supplemented with 0.4 IU/mL of LMW Heparin. 7. TECHNOVIEW LMW CONT MEIUM 4. TECHNOVIEW UFH CONT HIGH x 1.0 ml Set of high control plasmas for quality control of unfractionated Heparin (UFH) x 1.0 ml Set of medium control plasmas for the quality control of Low Molecular Weight (LMW) Heparin Control Medium plasmas are prepared from citrated plasmas supplemented with 0.9 IU/mL of LMW Heparin. Control plasmas are prepared from citrated plasmas supplemented with 0.5 IU/mL of unfractionated Heparin. Heparin is the most frequently used antithrombotic therapeutic drug. The biological activity of this sulfated glycosaminoglycan resides in its ability to accelerate (up to 2000-fold) the inhibitory effect of antithrombin (AT) on the coagulation proteases. 8. TECHNOVIEW LMW CONT HIGH x 1.0 ml Set of high control plasmas for the quality control of Low Molecular Weight (LMW) Heparin LMW Control High plasmas are prepared from citrated plasmas supplemented with 1.3 IU/mL of LMW Heparin. 59
7 1. TECHNOVIEW ORGARAN CAL SET Lyophilized plasmas ANTI-Xa x 1.0 ml Set of 5 plasmas for calibration of Sodium anaparoid (Orgaran ) measurements titrated and optimised using anti-xa assays. Calibrator plasma is prepared from citrated plasmas supplemented with different concentrations of Sodium anaparoid (Orgaran ). Orgaran Arixtra 4 5 Technoview Orgaran cal set Technoview Orgaran cont low Technoview Orgaran cont high Technoview Arixtra cal set Technoview Arixtra cont low 2. TECHNOVIEW ORGARAN CONT LOW x 1.0 ml Set of low control plasmas for the quality control of Sodium anaparoid (Orgaran ) Control Low plasmas are prepared from citrated plasmas supplemented with 0.50 IU/mL of Sodium anaparoid (Orgaran ). 6 Technoview Arixtra cont high 3. TECHNOVIEW ORGARAN CONT HIGH Sodium anaparoid (Orgaran ) is a polysaccharide anticoagulant, used as an alternative therapy to Heparin or low molecular weight Heparin (LMWH), when these latter drugs are contraindicated. TECHNOVIEW Orgaran Calibrator plasmas are prepared from citrated plasmas supplemented with different concentrations of Sodium anaparoid (Orgaran ). The plasma contains stabilizers but no bactericide additives x 1.0 ml Set of high control plasmas for the quality control of Sodium anaparoid (Orgaran ) Control High plasmas are prepared from citrated plasmas supplemented with 1.0 IU/mL of Sodium anaparoid (Orgaran ). 60
8 4. TECHNOVIEW ARIXTRA CAL SET x 1.0 ml Set of 5 plasmas for calibration and the quality control of Arixtra (Fondaparinux sodium) measurements, titrated and optimised using anti-xa assays. Calibrator plasma is prepared from citrated plasmas supplemented with different concentrations of Fondaparinux sodium Sodium (Arixtra ). 5. TECHNOVIEW ARIXTRA CONT LOW x 1.0 ml Set of low control plasmas for the quality control of Arixtra (Fondaparinux sodium) Control plasmas are prepared from citrated plasmas supplemented with 0.5 µg/ml of Fondaparinux sodium (Arixtra). 6. TECHNOVIEW ARIXTRA CONT HIGH Arixtra can be used as an anticoagulant for curative or preventive indications. Measuring the Arixtra concentration in patient s plasma allows monitoring the therapy and adjusting drug dosage. TECHNOVIEW Arixtra Calibrator plasmas are prepared from citrated plasmas supplemented with different concentrations of Fondaparinux sodium (Arixtra) x 1.0 ml Set of high control plasmas for the quality control of Arixtra (Fondaparinux sodium) High Control plasmas are prepared from citrated plasmas supplemented with 1.5 µg/ml of Fondaparinux sodium (Arixtra ). 61
9 Rivaroxaban Technoview Rivaroxaban cal set Technoview Rivaroxaban cont low Technoview Rivaroxaban cont medium Technoview Rivaroxaban cont high Apixaban Technoview Apixaban cal set Technoview Apixaban cont low Technoview Apixaban cont high Lyophilized plasmas ANTI-Xa NEW 7. TECHNOVIEW RIVAROXABAN CAL SET x 1.0 ml x 1.0 ml Set of 5 plasmas for calibration of rivaroxaban Calibrator plasmas are prepared from citrated plasmas supplemented with different concentrations of rivaroxaban. The plasma contains stabilizers but no bactericide additives. 8. TECHNOVIEW RIVAROXABAN CONT LOW x 1.0 ml Set of low control plasmas to be used for the quality control of rivaroxaban Control Low Plasmas are prepared from citrated plasmas supplemented with around 60 ng/ml of rivaroxaban. 9. TECHNOVIEW RIVAROXABAN CONT MEIUM x 1.0 ml Set of medium control plasmas to be used for the quality control of rivaroxaban Control Medium Plasmas are prepared from citrated plasmas supplemented with around 110 ng/ml of rivaroxaban. 62 Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer. In a number of countries it is marketed as Xarelto. 10. TECHNOVIEW RIVAROXABAN CONT HIGH x 1.0 ml Set of high control plasmas to be used for the quality control of rivaroxaban Control High Plasmas are prepared from citrated plasmas supplemented with around 300 ng/ml of rivaroxaban.
10 11. TECHNOVIEW APIXABAN CAL SET x 1.0 ml Set of calibration plasmas to be used for calibration of apixaban Calibrator plasma is prepared from citrated plasmas supplemented with different concentrations of apixaban. 12. TECHNOVIEW APIXABAN CONT LOW x 1.0 ml TECHNOVIEW Apixaban Control Plasma is a set of low control plasmas to be used for the quality control of apixaban Control Low Plasmas are prepared from citrated plasmas supplemented with around 120 ng/ml of apixaban. 13. TECHNOVIEW APIXABAN CONT HIGH x 1.0 ml TECHNOVIEW Apixaban Control Plasma is a set of high control plasmas to be used for the quality control of apixaban High Control plasmas are prepared from citrated plasmas supplemented with around 300 ng/ml of apixaban. Apixaban is an anticoagulant for the treatment of venous thromboembolic events. It is a direct factor Xa inhibitor. Measuring the Apixaban concentration in patients plasma allows monitoring the therapy and adjusting drug dosage. 63
11 Frozen Plasmas ANTI-Xa 1. CONTROL HNF / UFH CTHNF1 CTHNF2 Set of control plasmas for quality control of unfractionated Heparin (UFH) Control UFH plasmas are prepared from citrated plasmas supplemented with 2 different concentrations of WHO UFH standard chosen by customer Control HNF / UFH Control HBPM / LMWH Control ORGARAN 2. CONTROL HBPM / LMWH CTHBPM1 CTHBPM2 Features & benefits Supplemented with standard from european pharmacopoeia. Set of high control plasmas for the quality control of Low Molecular Weight (LMW) Heparin Control LMWH plasmas are prepared from citrated plasmas supplemented with 2 different concentrations of WHO LMWH standard chosen by customer. 64 Rapidly frozen in liquid Nitrogen Without any bovine additives No alteration due to lyophilization Ready to use in a couple of minutes Plasmas found negative for FA required tests Colour code for each plasma product Conditioned in plastic tubes, adaptable on STAR analyzers Can be stored up to 3 years at -40 C / -80 C 3. CONTROL ORGARAN CTO1-08 CTO2-08 Set of control plasmas for the quality control of Sodium anaparoid (Orgaran ) Control ORGARAN plasmas are prepared from citrated plasmas supplemented with 2different concentrations of Sodium anaparoid (Orgaran ).
Anticoagulants: Agents, Pharmacology and Reversal
Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University
More informationThe effect of the direct oral anticoagulants (DOACs) on haemostasis tests.
The effect of the direct oral anticoagulants (DOACs) on haemostasis tests. Emmanuel J Favaloro, Haematology, ICPMR, Pathology West, Sydney Centres for Thrombosis and Haemostasis, Westmead Hospital (with
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationNOACS/DOACS*: COAGULATION TESTS
NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international
More informationNew Anticoagulants: Laboratory Monitoring?? Dr Steve Kitchen Sheffield Haemostasis and Thrombosis centre UK
New Anticoagulants: Laboratory Monitoring?? Dr Steve Kitchen Sheffield Haemostasis and Thrombosis centre UK Ideal Anticoagulant (Hirsh et al 2004) High efficacy to safety ratio Predictable dose response
More informationOral Factor Xa Inhibitors and Clinical Laboratory Monitoring
Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring MELISSA L. WHITE ABSTRACT Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications.
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationPlease note that the uses described in the following page(s) have not been approved or cleared by FDA, with respect to the described assay or test.
Please note that the uses described in the following page(s) have not been approved or cleared by FDA, with respect to the described assay or test. In the US, the product is intended For Research Use Only.
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationPart IV Antithrombotics, Anticoagulants and Fibrinolytics
Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System
More informationManaging Bleeding in the Patient on DOACs
Managing Bleeding in the Patient on DOACs Spring 2016 Jean M. Connors, MD Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine, HMS Conflicts
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationThe information contained here may be very important to your practice. Please take a moment to review this document.
September 2017 Dear Healthcare Provider, The information contained here may be very important to your practice. Please take a moment to review this document. TEST BULLETIN T-SPOT TB TESTING Please see
More informationlaboratory monitoring of Direct Oral Anticoagulant: who, when and how Dr. Malake Naboulsi Hôpital Albert Haykel Laboratoire d hématologie.
laboratory monitoring of Direct Oral Anticoagulant: who, when and how Dr. Malake Naboulsi Hôpital Albert Haykel Laboratoire d hématologie. Disclosures Malake Naboulsi declare to meeting attendees that
More informationWolfgang Mueck *, Stephan Schwers and Jan Stampfuss
Mueck et al. Thrombosis Journal 2013, 11:10 REVIEW Open Access Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation
More informationHuman coagulation factor Xa, FXa ELISA Kit
Human coagulation factor Xa, FXa ELISA Kit Catalog No: E1613h 96 Tests Operating instruction www.eiaab.com FOR RESEARCH USE ONLY; NOT FOR THERAPEUTIC OR DIAGNOSTIC APPLICATIONS! PLEASE READ THROUGH ENTIRE
More informationBlood coagulation and fibrinolysis. Blood clotting (HAP unit 5 th )
Blood coagulation and fibrinolysis Blood clotting (HAP unit 5 th ) Vessel injury Antithrombogenic (Favors fluid blood) Thrombogenic (Favors clotting) 3 Major systems involved Vessel wall Endothelium ECM
More information3/25/2016. Objectives for Pharmacists. Stop the Bleeding! New Reversal Agents. Objectives for Pharmacy Technicians. Assessment Pre-test
Objectives for Pharmacists Stop the Bleeding! New Reversal Agents Gary D Peksa, Pharm.D., BCPS Clinical Pharmacy Specialist, Emergency Medicine Rush University Medical Center Review current strategies
More informationOverview of anticoagulants David Perry
Chapter 2 Overview of anticoagulants David Perry Historically anticoagulation involved the use of heparin and its derivatives or warfarin. However, the past few years have seen the introduction of a number
More informationLeading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient
Leading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient Emily Hutchison, PharmD BCPS Clinical Pharmacy Specialist, Trauma/Adult
More informationEvaluation Report. Eurolyser PT (INR) test kit (ST0180) on CUBE and smart analysers
Evaluation Report Eurolyser PT test kit (ST0180) on CUBE and smart analysers Locations Location 1: Eurolyser Diagnostica GmbH Operator: Simone Wieser Date: 30.06.2015 Specimens The specimens used for analysis
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationAdvances in Anticoagulation
May 18, 2017 Advances in Anticoagulation Wei Ling Lau, MD Assistant Professor, Nephrology University of California, Irvine Talk Outline High stroke risk in CKD population Warfarin off-target effects on
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationIdarucizumab for Dabigatran Reversal Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015; 373(6):
Idarucizumab for Dabigatran Reversal Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015; 373(6):511-520. Objective: To measure the safety of idarucizumab to reverse dabigatran anticoagulant effects
More informationIl laboratorio: verso una migliore definizione dei test
Il laboratorio: verso una migliore definizione dei test Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Dept. of Clinical Sciences and Community Health University of Milano Laboratory
More informationHEMATOLOGY AND COAGULATION ANALYTIC PROTOCOLS
1 of 6 Policy #: 800 (PLH-800-13) Initiated Date: 12/4/2002 Reviewed Date: 8/1/2016 Subject: HEMATOLOGY AND COAGULATION ANALYTIC PROTOCOLS Approved by: Laboratory Director, Jerry Barker (electronic signature)
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationComparison of Samples Obtained From 3.2% Sodium Citrate Glass and Two 3.2% Sodium Citrate Plastic Blood Collection Tubes Used in Coagulation Testing
Coagulation and Transfusion Medicine / GLASS VS PLASTIC IN HEMOSTASIS TESTING Comparison of Samples Obtained From 3.2% Sodium Citrate Glass and Two 3.2% Sodium Citrate Plastic Blood Collection Tubes Used
More informationADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL
Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic
More informationProthrombin (Human) ELISA Kit
Prothrombin (Human) ELISA Kit Catalog Number KA0496 96 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the Assay... 3 General
More informationNew drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle
New drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle CONCLUSIONS 1. Arrival of new anticoagulants is a Good Thing. CONCLUSIONS 1. Arrival of new anticoagulants
More informationBlood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy
Blood Thinner Agent Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy Outline: Blood thinner agent definition. anticoagulants drugs. Thrombolytics. Blood thinner agent Therapeutic interference
More informationComparison of Three Methods for Measuring Factor VIII Levels in Plasma
Coagulation and Transfusion Medicine / THREE FACTOR VIII ASSAYS Comparison of Three Methods for Measuring Factor VIII Levels in Plasma Wayne L. Chandler, MD, Chris Ferrell, MT(ASCP), Joo Lee, MT(ASCP),
More informationHeparin-Induced Thrombocytopenia (HIT)
Heparin-Induced Thrombocytopenia (HIT) Joshua Ononuju, Pharm. D. Owensboro Medical Health Systems Objectives Overview Pathogenesis Risk factors Clinical Presentation and Diagnosis Treatment goals and options
More informationInstruments smart solutions & service IGZ Instruments AG Räffelstrasse 32 CH 8045 Zürich
ADP (Adenosine-5 -Diphosphate) 101312 3 x 0.5mL ADP is a lyophilized preparation of adenosine-5 -diphosphate. The working concentration of the reconstituted reagent is 2 x 10-4 M. ADP is for use in routine
More informationTrue/False: Idarucizumab can be utilized for the management of bleeding associated with dabigatran.
Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or
More informationLaboratory Monitoring Measurement of the DOACs
1 Laboratory Monitoring Measurement of the DOACs ACC Anticoagulation Consortium Roundtable Meeting October 24, 2015 Adam Cuker, MD, MS Perelman School of Medicine University of Pennsylvania 2 Full disclosures
More informationBLOOD DISEASE RESEARCH FOUNDATION
BLOOD DISEASE RESEARCH FOUNDATION BLOOD DISEASE RESEARCH FOUNDATION The mission of Blood Disease Research Foundation is to support hematological research, e.g. by donating grants for thesis work and abstract
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationEdoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders Anticoagulants have a key role in the treatment of arterial and venous thromboembolic disorders.
More informationHEMOSTASIS Quality Time saving Economy Practicability Quality assurance Precision
Quality Time saving Economy Practicability Quality assurance Precision exclusive distributor of for France, Netherlands, Belgium and Luxembourg List of frozen reagents In 1992, Precision BioLogic began
More informationReversal Agents for NOACs (Novel Oral Anticoagulants)
Reversal Agents for NOACs (Novel Oral Anticoagulants) Current status and future challenges Paul A Reilly, PhD Clinical Research, Boehringer Ingelheim, Inc CSRC Symposium Washington DC Oct 18, 2016 Atrial
More informationRazvana Akbar Anticoagulation Pharmacist LTH
Razvana Akbar Anticoagulation Pharmacist LTH Platelet function Drugs affecting Coagulation; Anti-platelet drugs Anticoagulants Oral anticoagulants Parenteral anticoagulants Drugs affecting Haemoglobin
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationAdult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More informationM B Garvey. University of Toronto
Do I really need that test??? M B Garvey Professor Emeritus University of Toronto St Michael s Hospital No relevant conflicts of interest 1 HEMOSTASIS IS LIKE LOVE Everybody talks about it, nobody understands
More informationIs there a real need for new agents to optimize efficacy/safety balance
Anticoagulation in acute coronary syndrome Is there a real need for new agents to optimize efficacy/safety balance Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures
More informationDiscuss the role of idarucizumab for the management of bleeding associated with dabigatran
Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or
More informationPart II: Coagulation Laboratory: Methods, Standards & Cost Effective Testing. Donna D. Castellone ASCP Annual Meeting
Part II: Coagulation Laboratory: Methods, Standards & Cost Effective Testing Donna D. Castellone Understanding Coagulation Case Studies - clinical picture - analysis - diagnosis Case Study A 15 yr old
More informationFeedback from the EMA
Feedback from the EMA Jens Heisterberg, MD Danish Medicines Agency Is There a Role For Pharmacokinetic/Pharmacodynamics Guided Dosing For Novel Anticoagulants? CSRC Meeting, Washington D.C., December 3,
More informationEmergent Anticoagulation Reversal
U N C M E D I C A L C E N T E R G U I D E L I N E Emergent Anticoagulation Reversal I. PURPOSE: The purpose of these instructions is to provide guidelines for the reversal of or management of bleeding
More informationAnticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017
Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation
More informationMEASUREMENT OF ANTICOAGULANT EFFECTS OF NEW ORAL ANTICOAGULANTS PRACTICAL ASPECTS
MEASUREMENT OF ANTICOAGULANT EFFECTS OF NEW ORAL ANTICOAGULANTS PRACTICAL ASPECTS Désirée Coen Herak Department of Laboratory Diagnostics University Hospital Centre Zagreb WARFARIN ERA Warfarin monopoly
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationChange from lovenox to pradaxa
P ford residence southampton, ny Change from lovenox to pradaxa 14-11-2017 We wanted to put out a friendly reminder that the Ask 3 Teach 3 (A3T3) initiative is indeed full swing. This is an multidisciplinary
More informationNEW ORAL ANTICOAGULANTS: A VIEW FROM THE LABORATORY
NEW ORAL ANTICOAGULANTS: A VIEW FROM THE LABORATORY Jing Jin Clinical laboratory Scientist (MLS, ASCP) - Coagulation/Hematology Stanford University Hospital and Clinics 1 OBJECTIVES 1. Describe the mechanisms
More informationRazvana Akbar Anticoagulation Pharmacist LTH
Razvana Akbar Anticoagulation Pharmacist LTH Platelet function Drugs affecting Coagulation; Anti-platelet drugs Anticoagulants Oral anticoagulants Parenteral anticoagulants Drugs affecting Haemoglobin
More informationA Brief History of the World of Anticoagulation
A Brief History of the World of Anticoagulation Allison Burnett, PharmD, CACP, PhC Clinical Assistant Professor- UNM College of Rx Antithrombosis Stewardship Pharmacist University of New Mexico Hospital
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute lung injury (ALI) transfusion-related, 363 372. See also Transfusion-related acute lung injury (TRALI) ALI. See Acute lung injury
More informationInternal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation
Internal Quality Control in the Haemostasis laboratory Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation Why do we need Quality control? Philadelphia Enquirer Aug
More informationL iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche
L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Dept. of Clinical Sciences and Community Health University
More informationThe study has been approved by Ethics Commission. Informed consent has been given by all participants.
Evaluation of new 9NC Coagulation Tubes Background: Venous blood with sodium citrate is the most commonly obtained examination sample for coagulation determinations. The additive functions as an anticoagulant
More informationLaboratory monitoring of oral anticoagulants. A/Prof. Lee Lai Heng Haematology Singapore General Hospital
Laboratory monitoring of oral anticoagulants A/Prof. Lee Lai Heng Haematology Singapore General Hospital Relevant Disclosures Educational and Travel Grants Bayer, Leo, Bristol Meyer Squib Advisory Boards
More informationManagement of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline. Contents
Management of haemorrhage in patients taking DOACs/ NOACs (direct/ novel oral anticoagulants) Guideline Classification: Clinical Guideline Lead Author: Dr Rowena Thomas-Dewing, Consultant Haematologist
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationPharmacotherapy of Thrombo-embolic disorders
Pharmacotherapy of Thrombo-embolic disorders Intended Learning Objectives: 1. Define thromboembolic disorders 2. Identify risk factors, signs and symptoms of Venous thromboembolism. 3. Describe the processes
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationseminaires iris Mon patient prend un NACO, comment évaluer sa coagulation au Service des Urgences?
Mon patient prend un NACO, comment évaluer sa coagulation au Service des Urgences? Jonathan DOUXFILS, Department of pharmacy Faculty of Medicine University of Namur Séminaire IRIS Content Introduction
More informationPrimary Exam Physiology lecture 5. Haemostasis
Primary Exam Physiology lecture 5 Haemostasis Haemostasis Body s response for the prevention and cessation of bleeding. Broadly consists of: Primary Haemostasis - vascular spasm and platlet plug formation
More informationAntiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center
Antiplatelets and Anticoagulants Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Mechanism 2 http://www.medicinehack.com/2011/07/virchows-triad.html Mechanism 3 http://drtedwilliams.net/kb/index.php?pagename=coagulation%20cascade
More information2017 Oregon Dental Conference Course Handout
2017 Oregon Dental Conference Course Handout David Lasho, DDS, MSD Course 8171: Dental Management of Patients on Antithrombotic Medications Saturday, April 8 1 pm - 3 pm Dental Management of Patients on
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationAndexanet Alfa: Reversal agent for FXa Inhibitors
Andexanet Alfa: Reversal agent for FXa Inhibitors Grace Gilmore, Prof Ross Baker, Dr Jim Tiao, Dr Quintin Hughes, Dr Jasmine Tay, Scott McGregor WA Centre for Thrombosis and Haemostasis, Murdoch University,
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK University Hospitals NHS Foundation Trust Haematology and Transfusion Department Mindelsohn Way Edgbaston Contact: Tel: +44 (0) 121 371 5963
More informationPULMONARY EMBOLISM -CASE REPORT-
University Goce Delcev, Faculty of Medical sciences, Stip University Clinic of Cardiology, Skopje R. Of Macedonia PULMONARY EMBOLISM -CASE REPORT- Gordana Kamceva MD mr.sci Acknowledgment Marija Vavlukis
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationCoagulation, Haemostasis and interpretation of Coagulation tests
Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationMouse C-Peptide ELISA Kit
Mouse C-Peptide ELISA Kit Cat.No: DEIA4507 Lot. No. (See product label) Size 96T Intended Use The Mouse C-Peptide ELISA kit is for the quantitative determination of c-peptide in mouse serum, plasma, and
More informationEmergency Management of Patients on Direct Oral Anticoagulants (DOACs)
Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Dr Tina Biss Consultant Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust NE RTC Annual Education Symposium 11 th October
More informationDetermination of APTT factor sensitivity the misguiding guideline
International Journal of Laboratory Hematology ORIGINAL ARTICLE The Official journal of the International Society for Laboratory Hematology INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY Determination
More informationGenerate Knowledge Pre-Analytical Variables in the Coagulation Lab: Why Does It Matter?
Generate Knowledge Pre-Analytical Variables in the Coagulation Lab: Why Does It Matter? Paul Riley, PhD, MBA Pre-Analytical Variables: Objectives 1. Define Pre-Analytical variables 2. Explain how blood
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationHemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures
Hemostasis PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Disorders of Hemostasis - Hemophilia - von Willebrand Disease HEMOPHILIA A defect in the thrombin propagation phase
More informationJoost van Veen Consultant Haematologist
Joost van Veen Consultant Haematologist Bridging anticoagulation - conclusion Aim Questions What is the evidence? Does oral anticoagulation need to be stopped and if so when? When and at what dose is alternative
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More informationIntroduction to coagulation and laboratory tests
Introduction to coagulation and laboratory tests Marc Jacquemin Special Haemostasis Laboratory Center for Molecular and Vascular Biology University of Leuven Coagulation in a blood vessel: fibrin stabilises
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationPost-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose.
Medication Time to wait after last dose Post-procedure dose ok after hours Can pull catheter hours after last dose Can give next dose hours after pulling catheter Enoxaparin (Lovenox) Prophylactic dose
More informationPharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics
Italian Journal of Medicine 2013; volume 7(s8):1-7 Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics Luca Masotti, 1 Mauro Campanini 2 1 Internal Medicine,
More informationCHAPTER 17 Antithrombotic Agents Heparins
CHAPTER 17 Antithrombotic Agents Heparins Structure Mechanism of Action Pharmacokinetics Limitations of Unfractionated Heparin Heparin Induced Thrombocytopenia Heparin Rebound Low Molecular Weight Heparins
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationTissue type Plasminogen Activator Human Chromogenic Activity Assay Kit
ab108905 Tissue type Plasminogen Activator Human Chromogenic Activity Assay Kit Instructions for Use For the quantitative measurement of Human Tissue type Plasminogen Activator activity in cell culture
More informationNovel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology
Novel Anticoagulant Drugs by: Dr. M. Kamandi Fellowship of hematology and Oncology A-Novel Oral Anticoagulants A drug that is: safe and effective has predictable pharmacology has few drug drug and drug
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More information